Business Wire

Altasciences’ CEO Chris Perkin Recognized as PharmaVOICE Red Jacket Honoree

Share

Altasciences is proud to announce that CEO Chris Perkin has been recognized as a 2019 Red Jacket honoree. The Red Jacket Award was introduced by PharmaVOICE in 2014 to honor a select and distinguished group of leaders who have been lauded by their colleagues and peers numerous times as PharmaVOICE 100 designees for their many contributions to their companies and the industry at large. Chris has been a PharmaVOICE 100 designee every year since 2015, and, as a Red Jacket honoree, will be retiring the annual award for the lifetime achievement of the Red Jacket.

PharmaVOICE Red Jacket honorees:

  • Challenge us to think differently, act differently, and lead differently
  • Create opportunities to make what was once impossible — possible
  • Are focused beyond short-term gains and are committed to executing their long-term visions in a tightly regulated and competitive industry
  • Have a persistence of vision
  • Are truly transforming the life sciences industry to create better health outcomes for all
  • Are inspired leaders for today and tomorrow

Throughout Chris’ career, he has demonstrated a commitment to innovation, transformation, mentorship, and philanthropy. His entrepreneurial spirit and leadership have inspired Altasciences’ employees, peers, and company, and his influence is impacting the larger sphere of the life sciences industry.

I am honored to have been selected for this recognition, which would have been impossible without the unwavering support of the Altasciences team, our sponsors, and key collaborators. I know that, working together, we can continue making positive impacts in the ever-evolving, fast-paced life sciences marketplace,” said Chris Perkin, CEO of Altasciences and Red Jacket honoree.

About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements. Altasciences…helping sponsors get better drugs to the people who need them, faster.

Contact information

Julie-Ann Cabana
Altasciences
913 304-4505
jcabana@altasciences.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ferring and Igenomix Collaborate to Advance Care in Reproductive Medicine and Maternal Health4.6.2020 08:00:00 EESTPress release

Ferring Pharmaceuticals and Igenomix today announced a two-year research collaboration aimed at the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005784/en/ A new research hub will be created in Boston, bringing together scientists and expertise from both companies. The hub will focus on investigating molecular signatures, developing novel functional genomic systems and creating translational tools to study for embryo implantation, endometrial microbiome interaction and decidualization biology to drive innovative solutions for patients. “Today, 1 in 6 couples worldwide are affected by fertility issues, with embryo implantation being a critical step to improving success rates in assisted

European Steering Committee launch ‘A New Era in Diabetes Care’ report highlighting the need to improve the quality of care for people with type 2 diabetes and renal / cardiovascular complications4.6.2020 02:01:00 EESTPress release

A new expert-led report has today been launched to help outline key challenges and inequalities in the care of type 2 diabetes mellitus (T2DM) and its associated renal and cardiovascular complications, and highlight some Calls to Action to try and address these gaps for the 53 million Europeans living with T2DM.1 A New Era in Diabetes Care is a non-promotional disease awareness initiative that brings together a European Multidisciplinary Steering Committee of diabetes, nephrology and primary care experts, funded by Mundipharma International Limited. The report, authored by the Steering Committee, explores five main areas within the management of T2DM, chronic kidney disease (CKD) and cardiovascular disease (CVD): Healthcare professional and patient education on CKD and its signs Effective testing and interpretation of markers (clinical indicators) of CKD Greater understanding of the clinical management model amongst HCPs Use of shared decision-making to create an appropriate care plan

Celltrion Healthcare showcases positive 1-year data and budget impact analysis for novel subcutaneous formulation of infliximab in patients with rheumatoid arthritis at the European E-Congress of Rheumatology 20204.6.2020 01:01:00 EESTPress release

At the European E-Congress of Rheumatology 2020 (The European League Against Rheumatism (EULAR) 2020 E-Congress), Celltrion Healthcare today showcased three sets of data relating to a subcutaneous formulation of infliximab, Remsima® SC. The first study demonstrated no impact of body mass index (BMI) on clinical response to CT-P13 SC in patients with active rheumatoid arthritis (RA).1 The post-hoc study investigated the impact of BMI on clinical response to CT-P13 SC in part 2 of a phase I/III randomised controlled trial (RCT) in 165 patients throughout a 1-year treatment period.1 Patients were categorized into 3 groups; under/normal weight (<25kg/m2), overweight (≥25kg/m2, <30kg/m2), and obesity (≥30kg/m2) based on the WHO BMI classification. The three groups received at least one full dose of CT-P13 SC (after IV induction) in the initial treatment stage before week 30. The data show that the mean change from baseline of DAS28 (CRP) (-3.3, -3.1, -3.3 at week 54), duration of low diseas

euNetworks Secures Additional Growth Capital From IMCO and Stonepeak Infrastructure Partners3.6.2020 23:09:00 EESTPress release

euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has secured an additional €250 million of capital from the Investment Management Corporation of Ontario (“IMCO”), an investor since 2018, alongside a new commitment from a vehicle managed by Stonepeak Infrastructure Partners. Pro forma for the capital raise, Stonepeak will continue to own a majority stake in euNetworks. The equity commitment will be allocated to fund further organic growth, M&A and other general corporate purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200603005861/en/ euNetworks (Photo: Business Wire) euNetworks is focused on delivering high bandwidth data centre to data centre connectivity between and within cities in Europe. The company owns and operates deep fibre networks in 17 cities and also operates a highly differentiated long haul network that spans 15 countries. euNetworks

NetApp to Acquire Spot3.6.2020 23:03:00 EESTPress release

NetApp® (NASDAQ: NTAP), the leader in cloud data services, today announced it has entered into a definitive agreement to acquire Spot, a leader in compute management and cost optimization on the public clouds, to establish leadership in Application Driven Infrastructure. Digital transformation initiatives have accelerated and remain the top business priority, especially in today’s environment, and the public clouds offer the speed and flexibility needed to navigate this new normal as companies find to new ways to work, interact and do business. However, unoptimized clouds can be costly and slow down the business transformation. To address this challenge, an Application Driven Infrastructure translates the application’s workload patterns and drives the best possible level of performance and cost for storage and compute, all done while maintaining the contracted service-level agreement (SLA) and service-level objective (SLO). Together, NetApp and Spot’s Application Driven Infrastructure

TeleSign Helps Skype Screen Robocalls with Score3.6.2020 19:00:00 EESTPress release

TeleSign today announced a new partnership with Microsoft’s Skype to screen robocalls using the flagship digital identity solution Score. By implementing Score, Skype is able to action against calls that are likely of a fraudulent origin. In this capacity Score is able to behave as an inbound spam filter while also preventing other types of communication fraud such as International Revenue Share Fraud (IRSF). Since implementing the TeleSign solution, Skype has been able to action upon over one million fraudulent calls per day. Ravish Patel, Sr. Director Digital Identity Solutions, said, “Robocalling has caused a major customer experience issue for end-users and causes severe reputational damage for communication apps and services who are unaware of the point and scale of such sophisticated attacks. By leveraging a global network consortium and Score's supervised machine learning algorithm, we are able to analyze and effectively flag fraudulent incoming calls, thereby saving money and p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom